PDI, Inc. has signed a collaboration with a privately held molecular diagnostics company to commercialize its molecular diagnostic tests. The initial test to be commercialized is fully developed. For competitive reasons, the name of the company and the specific focus area of the initial test to be commercialized are not being disclosed at this time. PDI has paid the company an initial fee of $1.5 million and has received an option to purchase the company outright. The option price is dependent ...